Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference
New data highlight additional benefits beyond survival with the SynCardia Total Artificial Heart and preclinical progress for the next-generation Emperor system
TUCSON, Ariz., March 02, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Dr. Andre Simon, Vice President of Clinical Affairs, will deliver three scientific and educational presentations at the Technology and Heart Failure Therapeutics (THT) 2026 conference to be held in Boston from March 2
Dr. Andre Simon commented, “Total artificial heart therapy continues to evolve through both clinical experience and technological innovation. Our goal is not only survival, but meaningful recovery, improved quality of life, and preservation of transplant opportunity. Picard Medical’s participation at THT reflects the Company’s ongoing commitment to scientific exchange, physician education, and innovation in next generation artificial heart technology.”
More information on Dr. Simon’s three presentations is below:
Format: Scientific Abstract Presentation
Date and Time: Monday, March 2; 4:15 PM EST; HF Focus Station 2 | Ensemble C-D | Level 2
Title: “The Emperor Rises: First In Vitro and In Vivo Evaluation of SynCardia’s Electromechanical Total Artificial Heart”
Dr. Simon will present early laboratory and preclinical data demonstrating that the Emperor system preserves the proven physiologic performance of the SynCardia Total Artificial Heart. The fully implantable architecture is designed to eliminate transdermal pneumatic drivelines and enable improved mobility, quality of life, and long-term patient independence.
Format: Educational Lecture
Date and time: Tuesday, March 3; 3:28 PM EST; Ensemble E-F | Level 2
Title: “The Total Artificial Heart of the Future: My Wish List”
In this invited session, Dr. Simon will discuss the future evolution of total artificial heart therapy, including clinical priorities such as earlier intervention, organ recovery, improved patient selection, and the transition from bridge to transplant toward durable long-term support.
Format: Clinical Outcomes Presentation
Date and Time: Wednesday, March 4; 8:50 AM EST; Ensemble C-D | Level 2
Title: “Beyond Survival: Defining Success After Total Artificial Heart Implantation”
This presentation will highlight updated registry analyses showing that outcomes with the SynCardia Total Artificial Heart extend beyond survival to include stabilization, organ recovery, functional improvement, and preservation of transplant eligibility. Key findings include sustained clinical success in critically ill patients, improved outcomes in patients implanted earlier in their disease trajectory, strong recovery potential even in patients initially not eligible for transplant, and significant improvements in quality of life after early postoperative recovery. Renal and neurological outcomes remain major determinants of long-term success.
About THT 2026
Technology and Heart Failure Therapeutics (THT) 2026 is an international conference focused on advancing innovation in heart failure through emerging device, technology, and combination therapies. Sponsored by the Cardiovascular Research Foundation, THT brings together leading clinicians, researchers, and industry partners to share the latest clinical data, discuss regulatory and commercial pathways, and explore future trends shaping the management of advanced heart failure. The multidisciplinary program features cutting-edge scientific sessions, case-based discussions, and hands-on training designed to foster collaboration and improve patient outcomes.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
VIPCross-Asset Positioning Amid AI Earnings Scrutiny and the US Election
1. Markets diverged during the week. Between the October 23 and October 30 closes, BTC fell 4.78%, the Nasdaq 100 declined 1.98%, and gold and silver dropped 2.72% and 8.59%, respectively. The DAX, KOSPI, Nikkei 225 and Hang Seng advanced. We focus on differences in growth prospects, valuation sensitivity and risk exposures rather than applying a single directional view across assets. 2. Market reactions to Alphabet's and Intel's earnings brought returns on AI investment into focus. Attention is shifting from the scale of capital expenditure to revenue realization, margins and free cash flow. Lower interest rates can ease discount-rate pressure, but a sustained valuation recovery still requires support from both operating performance and financing conditions. 3. The November 3 US midterm elections and November 6 employment report are key events in the coming week. We monitor how post-election fiscal and legislative agendas may affect interest rates, the dollar and industry operating conditions. Our execution priorities are to manage leverage and concentration, retain margin and exit-liquidity buffers, and avoid treating a single political outcome as an automatic trading signal. 4. Following Binance's disclosure of a security incident, industry attention to endpoint protection, access segregation and coordinated incident response has increased. Key assets to monitor: BTC, the Nasdaq 100, crude oil and gold, alongside upcoming earnings from AAPL, AMD, PLTR, ARM, ANET and QCOM.
HYATT HOTELS CORP <H.N>: JEFFERIES RAISES TARGET PRICE TO $188 FROM $167
Italgas Raised to Buy From Hold by Berenberg
BANCORP INC <TBBK.O>: KBW CUTS TARGET PRICE TO $56 FROM $65
Crypto prices
More
